Physician profile
Daniel S Sa
NPI 1427075308
$2,244.77
in general payments reported to CMS, 2019-2025
30 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $25.00 · 2021: $26.93 · 2024: $1,601 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609 · Travel and Lodging: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.23 |
| Travel and Lodging | $360.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $360.94 | 2024 | Infinity |
| Genentech USA, INC. | $209.96 | 2024-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Astrazeneca Pharmaceuticals LP | $118.41 | 2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $113.90 | 2024-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $111.94 | 2019-2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $104.80 | 2024-2025 | Ponvory |
| Lundbeck LLC | $101.33 | 2024-2025 | Vyepti, Rexulti |
| Ucb, INC. | $91.32 | 2024-2025 | Briviact, Rystiggo |
| Sk Life Science, INC. | $71.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $70.13 | 2024-2025 | |
| Mdd US Operations, LLC | $67.88 | 2019 | |
| Allergan, INC. | $65.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $62.54 | 2024-2025 | Rexulti |
| Eisai INC. | $62.21 | 2024 | |
| Argenx US, INC. | $62.04 | 2024 | Vyvgart Hytrulo, Vyvgart |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $59.43 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $58.28 | 2024 | |
| Amgen INC. | $56.72 | 2024-2025 | Uplizna |
| Lilly USA, LLC | $53.44 | 2019-2025 | Amyvid |
| Livanova USA, INC. | $53.13 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $49.54 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $46.47 | 2024 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $39.15 | 2024-2025 | |
| Pfizer INC. | $37.60 | 2024-2025 | |
| Biogen, INC. | $23.77 | 2024 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $22.13 | 2019 | |
| Medline Industries LP | $20.57 | 2024 | |
| Abbvie INC. | $20.57 | 2024 | |
| Averitas Pharma INC. | $16.40 | 2024 | Qutenza |
| Supernus Pharmaceuticals, INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.